Rheumatoid arthritis (RA) is a chronic inflammatory multifactorial disorder affecting approximately 1% of population, with over 3000000 new cases annually. The principal pharmacological agents are nonsteroidal anti-inflammatory drugs (NSAID). Patients with rheumatoid arthritis are vulnerable to NSAID-associated gastrointestinal complications. Based on these findings we developed a new NSAID agent based on phenolic glycoside structure methyl (4-О-β-glucopyranosyloxy)-benzoic acid. In this study we evaluated the methyl (4-О-β-glucopyranosyloxy)-benzoic acid therapeutic effect in adjuvant-induced rat arthritis compared to etoricoxib effect. According to the results, methyl (4-О-β-glucopyranosyloxy)-benzoic acid activity was superior to etoricoxib, paw volume returned to the initial value 2 days early, than it did in etoricoxib group. Therefore, methyl (4-О-β-glucopyranosyloxy)-benzoic acid might contest to the modern antirheumatic drug etoricoxib.